NextCure, Inc. filed a current report on November 20, 2026, disclosing that its board of directors set December 8, 2026 as the record date for a planned distribution of contingent value rights to stockholders in connection with its previously announced merger with Avere Therapeutics, Inc.

Key Highlights

  • Record date set: The board determined December 8, 2026 as the record date for the Pre-Closing Distribution, described as the third business day prior to the anticipated First Effective Time.
  • Distribution date expected: The distribution date is expected to occur on December 14, 2026, one business day after the First Effective Time.
  • One CVR per share: Each holder of record of Common Stock or Preferred Stock will be entitled to receive one CVR for each share held as of the record date.
  • CVR value tied to legacy assets: Each CVR represents the right to receive 90% of gross proceeds, if any, from the sale, transfer, license, or other disposition of the company's pre-merger legacy assets during the CVR Term, less permitted deductions.
  • Conditioned on First Effective Time: Payment of the Pre-Closing Distribution is conditioned on the occurrence of the First Effective Time.
  • Merger Agreement origin: The distribution stems from an Agreement and Plan of Merger and Reorganization entered into on July 14, 2026, among NextCure, Avere Therapeutics, and two merger subsidiaries.

NextCure Board Establishes CVR Distribution Timeline Ahead of Avere Merger Close

According to the filing, NextCure, Inc. (NASDAQ:NXTC) disclosed under Item 7.01 Regulation FD that its board of directors, on November 20, 2026, set the record date for the Pre-Closing Distribution at December 8, 2026. The company described this date as the third business day prior to the anticipated First Effective Time of its merger with Avere Therapeutics, Inc. The distribution date is expected to be December 14, 2026, one business day after the First Effective Time, though the filing noted the payment remains conditioned on that event occurring.

The filing explained that each holder of record of the company's Common Stock, par value $0.001 per share, and Preferred Stock, par value $0.001 per share, will receive one CVR for each outstanding share held as of the record date, subject to exceptions set forth in the Merger Agreement. Each CVR, governed by the Contingent Value Rights Agreement attached as Exhibit E to the Merger Agreement, represents a contractual right to receive 90% of the gross proceeds, if any, derived from any consideration paid to the company during the CVR Term as a result of the sale, transfer, license, or other disposition of rights to develop and commercialize the company's pre-merger legacy assets, less permitted deductions as defined in that agreement.

The company noted that the underlying Merger Agreement was entered into on July 14, 2026, by and among NextCure, Avere Therapeutics, Neptune Merger Sub Corp. (a wholly owned subsidiary of NextCure), and Neptune Second Merger Sub, LLC (also a wholly owned subsidiary of NextCure). The filing was signed by Steven P. Cobourn, Chief Financial Officer, on behalf of NextCure.

What Was Disclosed

NextCure disclosed the board-determined record date of December 8, 2026 and expected distribution date of December 14, 2026 for a one-CVR-per-share Pre-Closing Distribution, with each CVR carrying the right to 90% of qualifying legacy-asset proceeds during the CVR Term, less permitted deductions.